Alterity Therapeutics sets November 20 annual meeting

Director nominations must be received in writing at Alterity’s registered office by October 2, 2026, before its November 20 AGM.

Rhea-AI Filing Summary

Alterity Therapeutics Limited (ATHE) said its next Annual General Meeting will be held at 11.00am AEDT on November 20, 2026. Written director nominations must be received at the company’s registered office no later than 5.00pm AEST on October 2, 2026.

Shareholders will receive further AGM details in a separate Notice of Meeting.

Filing Explained

The filing also states that this Form 6-K is being incorporated by reference into the listed Form S-8 and Form F-3 registration statements.

Key Figures

AGM date: November 20, 2026 Director nomination deadline: October 2, 2026, by 5.00pm AEST

2 metrics

AGM date November 20, 2026 Scheduled for 11.00am AEDT.

Director nomination deadline October 2, 2026, by 5.00pm AEST Written nominations must be received at the company’s registered office.

Key Terms

Annual General Meeting, director nominations, ASX Listing Rule 3.13.1

3 terms

Annual General Meeting regulatory

"next Annual General Meeting (AGM) will be held"

director nominations regulatory

"closing date for director nominations"

Director nominations are proposals to appoint specific people to a company's board of directors, put forward for shareholder consideration and typically decided by a vote. The board steers strategy, hires and evaluates executives, and watches over risk and finances—like choosing a school's board or a homeowners’ association—so who is nominated affects governance quality, company direction, and ultimately potential investor returns.

ASX Listing Rule 3.13.1 regulatory

"in accordance with ASX Listing Rule 3.13.1"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 06:03 AM Accepted by SEC EDGAR 09/25/2026 - 06:02 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Date of AGM and Closing Date for Director Nominations

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: September 25, 2026

2

Exhibit 99.1

25 September 2026

ASX Announcement

DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS

Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) (Alterity or the Company) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11.00am (AEDT) on Friday 20 November 2026.

In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Friday 2 October 2026. Any nominations must be received in writing no later than 5.00pm (AEST) on Friday 2 October 2026 at the Company’s registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly.  The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website at www.alteritytx.com.

For further information, please contact:

Abby Macnish Niven

CFO & Company Secretary

T:            +61 3 9349 4906

E:            cfo@alteritytx.com

Alterity Therapeutics Limited

Level 15, 500 Collins Street, Melbourne, VIC 3000 Australia

T: +61 (0)3 9349 4906 | www.alteritytx.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 5.7 KB